• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Tenormin (atenolol) Tablets


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- April 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.


Summary View

Sections Modified

PRECAUTIONS

  • Drug Interactions
    • Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects...
    • Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta blockers...
    • Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate...

 

The April 2008 Label not available at this site.